In following the tumor/huPBMCs co-grafting model, m3s193 BsAb performed a similar tumor inhibitory activity with dose dependency, while the control mAb did not show activity at the high dosage, which was due to the existence of CD8+ and CD4+ T cells in the tumor micro-environment mediated by BsAb (Figure 6). The gene discussed is CD8A; the disease is neoplasm.